Raymond James Financial
SPRO icon

Raymond James Financial’s Spero Therapeutics SPRO Stock Holding History

Raymond James Financial’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
+521,705
New +$1.36M ﹤0.01% 3891
2025
Q3 		– Sell
-3,082
Closed -$8.94K – 6521
2025
Q2 		$8.94K Buy
+3,082
New +$4.43K ﹤0.01% 5966

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Raymond James Financial's SPRO Position: Q2 2026 in Review

Raymond James Financial opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 521,705 shares worth $1.15M. The stake represents ﹤0.01% of the portfolio and ranks #3891 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in SPRO as recently as Q2 2025.

Raymond James Financial first reported a position in SPRO in Q2 2025 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Raymond James Financial held 521,705 shares of Spero Therapeutics worth $1.15M as of Q2 2026.
  • Spero Therapeutics was a new Raymond James Financial position in Q2 2026.
  • Spero Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3891 holding.
  • Raymond James Financial first reported a position in Spero Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 59 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.